Tag: point of care molecular diagnostics market trends

  • Point-Of-Care Molecular Diagnostics Market Growth Is Accelerating As Industry Transformation Continues

    Point-Of-Care Molecular Diagnostics Market Growth Is Accelerating As Industry Transformation Continues

    Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

    The point-of-care molecular diagnostics sector is experiencing rapid expansion, driven by technological advancements and an increasing need for swift diagnostic solutions. This market’s evolution reflects growing healthcare demands and innovations aimed at improving early disease detection and patient management. Let’s explore the current market size, key drivers, major players, and emerging trends shaping this important healthcare segment.

    Point-of-Care Molecular Diagnostics Market Size and Growth Outlook

    The point-of-care molecular diagnostics market has witnessed impressive growth recently, with its size expected to rise from $3.98 billion in 2025 to $4.58 billion in 2026, representing a compound annual growth rate (CAGR) of 15.0%. Looking ahead, the market is projected to expand further, reaching $7.91 billion by 2030 at a CAGR of 14.7%. Factors contributing to this surge include the growing adoption of home-based molecular testing, increased investment in rapid diagnostic infrastructure, broader use in respiratory and oncology testing, greater integration of cloud-based diagnostic platforms, and a heightened focus on early disease detection. Key trends anticipated during this period encompass the widespread adoption of rapid molecular testing solutions, the rise of decentralized diagnostics, enhanced automated sample processing, expansion of syndromic testing panels, and efforts to reduce turnaround times.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7046&type=smp

    Primary Factors Contributing to Point-of-Care Molecular Diagnostics Market Growth

    The rising incidence of infectious and respiratory diseases is a major factor propelling the growth of the point-of-care molecular diagnostics market. Respiratory infections caused by viruses or bacteria affect the respiratory tract and spread through coughing, sneezing, or direct contact. These illnesses often require a combination of inhalers, oral and intravenous medications, and point-of-care molecular diagnostic tests to provide effective treatment.

    To illustrate, data from the UK Health Security Agency in June 2024 showed a sharp increase in influenza-related critical care admissions within NHS trusts in England. Between week 40 of 2022 and week 15 of 2023, there were 1,681 such admissions reported across 108 trusts, compared to 182 admissions across 114 trusts in the previous season, which rose to 316 by week 39 of 2022. This substantial rise in infectious and respiratory cases highlights the urgent need for timely diagnostic testing, supporting market growth.

    Access The Complete Point-Of-Care Molecular Diagnostics Market Report:

    https://www.thebusinessresearchcompany.com/report/point-of-care-molecular-diagnostics-global-market-report

    Detailed Breakdown of the Point-of-Care Molecular Diagnostics Market Segments

    This market is segmented in the report based on product types, applications, and end-users. The product category includes Assays and Kits, as well as Instruments and Analyzers. Applications cover Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), Hospital-Acquired Infections (HAIs), and Bloodstream and Sepsis-Related Infections. End-users comprise Decentralized Labs, Hospitals, Home Care, and Assisted Living Healthcare Facilities.

    Within Assays and Kits, subsegments feature Nucleic Acid Amplification Tests (NAATs), Rapid Diagnostic Tests, Molecular Detection Kits, and Reagents and Consumables. Instruments and Analyzers include microfluidic devices and point-of-care analyzers, emphasizing the diversity of available technologies.

    Innovative Advances Transforming the Point-of-Care Molecular Diagnostics Industry

    Leading market players are focused on enhancing their portfolios by adopting cutting-edge technologies, including enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, and DNA microarrays. These innovations aim to accelerate test result times while minimizing costs.

    For example, in May 2023, US-based Sensible Diagnostics unveiled a 10-minute point-of-care PCR system. Drawing from Curative’s extensive pandemic testing experience—having conducted over two million molecular point-of-care COVID-19 tests—this platform delivers rapid results, demonstrating the sector’s drive towards improving efficiency and accessibility.

    Key Players Shaping the Point-of-Care Molecular Diagnostics Market

    Several major companies maintain a significant presence in this market, including Abbott Laboratories, F Hoffmann La Roche Ltd, BioMérieux SA, Hologic Inc, Becton Dickinson and Company, Siemens Healthineers AG, QuidelOrtho Corporation, Bio Rad Laboratories Inc, Qiagen N V, Biocartis Group NV, DiaSorin S p A, SD Biosensor Inc, Cue Health Inc, Visby Medical Inc, Binx Health Inc, Molbio Diagnostics Pvt Ltd, Credo Diagnostics Biomedical Pvt Ltd, Genetron Health, Mammoth Biosciences Inc, and Seegene Inc. These firms play a vital role in driving innovation and expanding market reach.

    Regional Market Leaders and Growth Prospects

    In 2025, North America accounted for the largest share of the point-of-care molecular diagnostics market. However, the Asia-Pacific region is expected to experience the fastest growth during the forecast period. The market analysis includes comprehensive coverage of regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a broad perspective on global market dynamics.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Point-Of-Care Molecular Diagnostics Market Future Outlook Showing Expansion Toward $7.91 Billion by 2030

    Point-Of-Care Molecular Diagnostics Market Future Outlook Showing Expansion Toward $7.91 Billion by 2030

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Size Increase Is Anticipated For The Point-Of-Care Molecular Diagnostics Market Over The 2026–2030 Period?

    The point-of-care molecular diagnostics market size has seen rapid growth in recent years. This market is expected to expand from $3.98 billion in 2025 to $4.58 billion in 2026, at a compound annual growth rate (CAGR) of 15.0%. Historically, this expansion has been driven by factors including the increasing prevalence of infectious diseases, the wider availability of emergency diagnostic testing, a growing demand for rapid clinical decision support, continuous improvements in molecular assay technologies, and the increasing utilization of point-of-care diagnostics in hospitals.

    The point-of-care molecular diagnostics market is projected for swift expansion in the coming years. Its valuation is anticipated to reach $7.91 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.7%. This expansion during the projection period stems from factors such as the greater acceptance of home molecular testing, increased funding in rapid diagnostic facilities, broader uses for respiratory and oncology tests, expanding integration of cloud-based diagnostic systems, and a sharpened focus on detecting diseases earlier. Key developments anticipated within the forecast timeframe encompass the wider embrace of rapid molecular testing platforms, a heightened need for decentralized diagnostic approaches, increasing incorporation of automated sample handling, the broadening of syndromic testing panels, and an improved emphasis on quick result delivery.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7046&type=smp

    Which Major Factors Are Driving The Expansion Of The Point-Of-Care Molecular Diagnostics Market?

    The swift increase in the occurrence of infectious and respiratory diseases is anticipated to notably fuel the expansion of the point-of-care molecular diagnostics market. Respiratory infections, such as viruses or bacteria, stem from microorganisms that affect the respiratory system. These microbes can spread via coughing, sneezing, or direct physical contact. The management of severe respiratory conditions involves various inhalers, oral medications, intravenous treatments, and point-of-care molecular diagnostic methods to treat patients. For instance, in June 2024, as reported by the UK Health Security Agency, a UK-based government agency, between week 40 of 2022 and week 15 of 2023, 108 NHS trusts in England documented 1,681 critical care admissions for confirmed influenza. In contrast, the preceding season recorded 182 admissions across 114 trusts, escalating to 316 by week 39 of 2022. Hence, the rapid incidence of infectious and respiratory diseases and associated mortality will propel the point-of-care molecular diagnostics market.

    How Is The Point-Of-Care Molecular Diagnostics Market Segmented Across Key Categories?

    The point-of-care molecular diagnostics market covered in this report is segmented –

    1) By Product: Assays And Kits, Instruments And Analyzers

    2) By Application: Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), Hospital-Acquired Infections (HAIs), Bloodstream and Sepsis-Related Infections

    3) By End-User: Decentralized Labs, Hospitals, Home Care, Assisted Living Healthcare Facilities

    Subsegments:

    1) By Assays And Kits: Nucleic Acid Amplification Tests (NAATs), Rapid Diagnostic Tests, Molecular Detection Kits, Reagents And Consumables

    2) By Instruments And Analyzers: Microfluidic Devices, Point-of-Care Analyzers

    Which Upcoming Trends Are Expected To Influence The Point-Of-Care Molecular Diagnostics Market?

    Leading companies in the point-of-care molecular diagnostics market are concentrating on providing technologically advanced solutions to bolster their market position. These organizations are deploying next-generation point-of-care molecular diagnostics technologies and associated services, such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, and DNA microarrays, among others. These advancements are being implemented on POC devices to accelerate analysis times and lower costs. For instance, in May 2023, Sensible Diagnostics, a US-based diagnostics company, introduced a 10-minute point-of-care PCR system. Sensible Diagnostics is leveraging the expertise Curative gained from its diagnostics business during the pandemic. The firm stated it has performed more than two million molecular point-of-care COVID-19 tests, and its PCR platform boasts a 10-minute time-to-result.

    Who Are The Dominant Players Shaping The Point-Of-Care Molecular Diagnostics Market Landscape?

    Major companies operating in the point-of-care molecular diagnostics market are Abbott Laboratories, F Hoffmann La Roche Ltd, BioMérieux SA, Hologic Inc, Becton Dickinson and Company, Siemens Healthineers AG, QuidelOrtho Corporation, Bio Rad Laboratories Inc, Qiagen N V, Biocartis Group NV, DiaSorin S p A, SD Biosensor Inc, Cue Health Inc, Visby Medical Inc, Binx Health Inc, Molbio Diagnostics Pvt Ltd, Credo Diagnostics Biomedical Pvt Ltd, Genetron Health, Mammoth Biosciences Inc, Seegene Inc

    Read the full point-of-care molecular diagnostics market report here:

    https://www.thebusinessresearchcompany.com/report/point-of-care-molecular-diagnostics-global-market-report

    Which Region Currently Holds The Largest Share Of The Point-Of-Care Molecular Diagnostics Market?

    North America was the largest region in the point-of-care molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Point-Of-Care Molecular Diagnostics Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=7046&type=smp

    Browse Through More Reports Similar to the Global Point-Of-Care Molecular Diagnostics Market 2026, By The Business Research Company

    Molecular Diagnostics Devices And Equipment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-devices-and-equipment-global-market-report

    Point Of Care Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-global-market-report

    Biomarker Clinical Phase Outsourcing Services Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Point-Of-Care Molecular Diagnostics Sector Forecast Shows Robust Momentum, Climbing to $7.91 Billion With 14.7% CAGR

    Point-Of-Care Molecular Diagnostics Sector Forecast Shows Robust Momentum, Climbing to $7.91 Billion With 14.7% CAGR

    Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company

    What upper market value could the Point-Of-Care Molecular Diagnostics Market reach by 2030 starting from 2026 levels?

    The point-of-care molecular diagnostics market has experienced significant expansion in its size over recent years. Forecasts indicate it will expand from $3.98 billion in 2025 to $4.58 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.0%. Factors contributing to its historical growth include the rising occurrence of infectious diseases, an increase in emergency diagnostic testing, a greater need for quick clinical decision support, advancements in molecular assay technologies, and the expanded adoption of POC diagnostics within hospital settings.

    The point-of-care molecular diagnostics market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $7.91 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.7%. Factors contributing to this growth during the forecast period include the greater embrace of home-based molecular testing, augmented investments in rapid diagnostics infrastructure, the broadening of respiratory and oncology testing applications, the increasing incorporation of cloud-based diagnostic platforms, and a heightened emphasis on detecting diseases early. Key trends defining the forecast period encompass a surge in the adoption of rapid molecular testing platforms, a heightened demand for decentralized diagnostic solutions, the expanding integration of automated sample processing, a wider array of syndromic testing panels, and an amplified focus on achieving quick turnaround times.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7046&type=smp

    Which Drivers Are Influencing Long-Term Growth In The Point-Of-Care Molecular Diagnostics Market?

    The escalating prevalence of infectious and respiratory diseases is anticipated to significantly fuel the expansion of the point-of-care molecular diagnostics market. Respiratory infections, stemming from microorganisms like viruses or bacteria, impact the respiratory system, with transmission occurring through coughing, sneezing, or direct touch. Addressing severe respiratory conditions often involves a range of treatments including inhalers, oral medications, intravenous therapies, and point-of-care molecular diagnostic solutions for patient recovery. For example, in June 2024, the UK Health Security Agency, a UK-based government agency, reported that from week 40 of 2022 to week 15 of 2023, 108 NHS trusts in England documented 1,681 critical care admissions for confirmed influenza. This figure stands in stark contrast to the previous season, which recorded 182 admissions across 114 trusts, rising to 316 by week 39 of 2022. Thus, the rapid increase in infectious and respiratory diseases and related deaths is set to drive the point-of-care-molecular diagnostics market.

    How Is The Point-Of-Care Molecular Diagnostics Market Divided Into Segments?

    The point-of-care molecular diagnostics market covered in this report is segmented –

    1) By Product: Assays And Kits, Instruments And Analyzers

    2) By Application: Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), Hospital-Acquired Infections (HAIs), Bloodstream and Sepsis-Related Infections

    3) By End-User: Decentralized Labs, Hospitals, Home Care, Assisted Living Healthcare Facilities

    Subsegments:

    1) By Assays And Kits: Nucleic Acid Amplification Tests (NAATs), Rapid Diagnostic Tests, Molecular Detection Kits, Reagents And Consumables

    2) By Instruments And Analyzers: Microfluidic Devices, Point-of-Care Analyzers

    Which Trends Are Guiding The Evolution Of The Point-Of-Care Molecular Diagnostics Market?

    Leading companies within the point-of-care molecular diagnostics market are concentrating on delivering sophisticated technological solutions to enhance their presence. These firms are deploying next-generation point-of-care molecular diagnostics technologies and associated services, including enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, DNA microarrays, among others, for implementation on POC devices designed to quicken analysis times and reduce expenses. An example of this is Sensible Diagnostics, a US-based diagnostics company, which introduced a 10-minute point-of-care PCR system in May 2023. Sensible Diagnostics is drawing upon the expertise Curative acquired through its diagnostics operations during the pandemic. The company reported having processed more than two million molecular point-of-care COVID-19 tests, and its PCR platform boasts a 10-minute turnaround time for results.

    Which Major Industry Participants Are Leading The Point-Of-Care Molecular Diagnostics Market Growth?

    Major companies operating in the point-of-care molecular diagnostics market are Abbott Laboratories, F Hoffmann La Roche Ltd, BioMérieux SA, Hologic Inc, Becton Dickinson and Company, Siemens Healthineers AG, QuidelOrtho Corporation, Bio Rad Laboratories Inc, Qiagen N V, Biocartis Group NV, DiaSorin S p A, SD Biosensor Inc, Cue Health Inc, Visby Medical Inc, Binx Health Inc, Molbio Diagnostics Pvt Ltd, Credo Diagnostics Biomedical Pvt Ltd, Genetron Health, Mammoth Biosciences Inc, Seegene Inc

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/point-of-care-molecular-diagnostics-global-market-report

    Which Geographic Areas Are Emerging As Strong Markets For The Point-Of-Care Molecular Diagnostics Market?

    North America was the largest region in the point-of-care molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Point-Of-Care Molecular Diagnostics Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=7046&type=smp

    Browse Through More Reports Similar to the Global Point-Of-Care Molecular Diagnostics Market 2026, By The Business Research Company

    Molecular Diagnostics Devices And Equipment Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-devices-and-equipment-global-market-report

    Point Of Care Diagnostics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-global-market-report

    Biomarker Clinical Phase Outsourcing Services Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

  • Global Point-Of-Care Molecular Diagnostics Market Revenue and Share Analysis Through 2029

    Global Point-Of-Care Molecular Diagnostics Market Revenue and Share Analysis Through 2029

    Uncover key drivers, emerging technologies, and competitive movements shaping the point-of-care molecular diagnostics market from 2025–2034 with trusted insights from The Business Research Company

    What Is The Projected Valuation Of The Point-Of-Care Molecular Diagnostics Market In The Period 2029-2034?

    The point-of-care molecular diagnostics market has seen substantial growth in its size recently. It is projected to expand from $3.55 billion in 2024 to $3.98 billion in 2025, at a compound annual growth rate (CAGR) of 12.0%. The market’s historical growth can be attributed to an increasing requirement for quick disease diagnosis, a rise in infectious disease outbreaks, the expansion of telemedicine and remote testing, regulatory support for point-of-care diagnostics, and the need for personalized and precision medicine.

    The point-of-care molecular diagnostics market size is projected to experience substantial expansion in the coming years, anticipated to reach $6.92 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.8%. This anticipated growth during the forecast period can be attributed to factors such as the miniaturization of diagnostic devices, the broader application of POC testing for cancer and genetic diseases, the development of customized molecular diagnostics for various uses, the incorporation of AI and machine learning for data analysis, and enhanced surveillance of emerging infectious diseases. Key trends expected within the forecast timeframe encompass lab-on-a-chip and microfluidic technologies, advancements in digital health and smartphone-based diagnostics, preparedness for point-of-care COVID-19 and future pandemics, AI-driven predictive diagnostics, and the rise of CRISPR-based molecular testing.

    Access A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7046&type=smp

    What Strategic Drivers Are Accelerating The Point-Of-Care Molecular Diagnostics Market Expansion?

    The point-of-care molecular diagnostics market is anticipated to experience substantial growth, driven by the escalating incidence of infectious and respiratory ailments. These infections, often caused by microorganisms like viruses or bacteria affecting the respiratory system, transmit primarily through coughing, sneezing, or direct contact. Treatment for these conditions, particularly severe cases, encompasses various options such as inhalers, oral and intravenous medications, and increasingly, point-of-care molecular diagnostics for patient care. Illustratively, figures from the Office for National Statistics, a recognized UK national statistics institute, revealed that by the week ending December 9, 2022, in England, infection rates had risen among individuals aged 35 to 69 years and those within school years 12 to 24 years. Consequently, the widespread and rapid incidence of infectious and respiratory diseases, along with associated mortalities, is poised to propel the point-of-care molecular diagnostics market.

    What Is The Detailed Segment Distribution Of The Point-Of-Care Molecular Diagnostics Market?

    The point-of-care molecular diagnosticsmarket covered in this report is segmented –

    1) By Product And Service: Assays And Kits, Instruments And Analyzers, Software And Services

    2) By Technology: Reverse Transcription – Polymerase Chain Reaction (RT-PCR), In Situ Hybridization, Sequencing

    3) By Application: Respiratory Diseases, Hospital Acquired Infections (HAIs), Cancer/Oncology, Hepatitis, Hematology

    4) By End-User: Decentralized Labs, Hospitals, Home Care, Assisted Living Healthcare Facilities

    Subsegments:

    1) By Assays And Kits: Nucleic Acid Amplification Tests (NAATs), Rapid Diagnostic Tests, Molecular Detection Kits, Reagents And Consumables

    2) By Instruments And Analyzers: PCR Machines, Microfluidic Devices, Sequencers, Point-of-Care Analyzers

    3) By Software And Services: Data Management Software, Cloud-Based Solutions, Technical Support And Maintenance Services, Consultation And Training Services

    How Are Global Trends Impacting The Development Of The Point-Of-Care Molecular Diagnostics Market?

    Technological innovation is a major and growing trend in the point-of-care molecular diagnostics market. Key companies in the point-of-care molecular diagnostics market are striving to provide advanced technological solutions to strengthen their market position. These companies are adopting next-generation point-of-care molecular diagnostics technology solutions and related services, such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, and DNA microarrays, among others, for implementation on POC devices to achieve faster analysis times and lower costs. For instance, in May 2023, Sensible Diagnostics, a US-based diagnostics company, unveiled a 10-minute point-of-care PCR system. Sensible Diagnostics is leveraging the experience Curative gained from its diagnostics business during the pandemic. The firm reported that it has performed over two million molecular point-of-care COVID-19 tests, and its PCR platform delivers results in 10-minutes.

    Who Are The Major Stakeholders Operating In The Point-Of-Care Molecular Diagnostics Market?

    Major companies operating in the point-of-care molecular diagnostics market include Abbott Laboratories, F Hoffmann-La Roche Ltd., BioMérieux SA, Danaher Corporation, Quidel Corporation, BioMerieux SA, Bio-Rad Laboratories Inc., Sysmex Corporation, Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Biogenex Laboratories Inc., Cepheid Inc., Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Prometheus Laboratories Inc., Ventana Medical Systems Inc., Vermillion Inc., Guardant Health Inc., Exact Sciences Corporation, Biocartis Group NV, ArcherDx Inc., Bio-Techne Corporation, AccuBiotech Co. Ltd., Becton, Dickinson and Company, Chembio Diagnostics Inc., Credo Diagnostics Biomedical Pvt. Ltd., EKF Diagnostics, GenePOC Inc.

    Download The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/point-of-care-molecular-diagnostics-global-market-report

    Which Region Is Projected To Achieve The Fastest Growth In The Point-Of-Care Molecular Diagnostics Market?

    North America was the largest region in the point-of-care molecular diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Get A Report Customized For You Here:

    https://www.thebusinessresearchcompany.com/customise?id=7046&type=smp

    Browse Through More Reports Similar to the Global Point-Of-Care Molecular Diagnostics Market 2025, By The Business Research Company

    Point Of Care Diagnostics Devices And Equipment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

    Molecular Diagnostics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-global-market-report

    Molecular Diagnostics Devices And Equipment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-devices-and-equipment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model